Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.53 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 3/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048929 | 0.96 | TACR1 (0.51) | TACR1FKBP4 | |
| SCHEMBL410223 | 0.95 | FKBP4 (0.54) | TACR1FKBP4ITGB1ITGA4CMA1 | |
| SCHEMBL7076149 | 0.89 | FKBP4 (0.56) | TACR1FKBP4XIAPF2PRSS1 | |
| SCHEMBL7355900 | 0.89 | TACR1 (0.51) | TACR1FKBP4CMA1 | |
| SCHEMBL3667052 | 0.87 | FKBP4 (0.58) | TACR1FKBP4 | |
| SCHEMBL522116 | 0.84 | TACR1 (0.44) | TACR1FKBP4 | |
| SCHEMBL14027241 | 0.84 | FKBP4 (0.65) | TACR1FKBP4F2PRSS1PRSS2 | |
| SCHEMBL3277774 | 0.84 | FKBP4 (0.57) | TACR1FKBP4 | |
| SCHEMBL6058133 | 0.84 | OPRM1 (0.56) | TACR1FKBP4 | |
| SCHEMBL1295326 | 0.84 | F2 (0.54) | TACR1FKBP4XIAPF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056935-B2 | Rotamase enzyme activity inhibitors | GPI NIL HOLDINGS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6686357-B1 | BENZIMIDAZOLO-PIPERIDINE COMPOUND | PFIZER, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6562964-B1 | Inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders | PFIZER INC | 2003-05-13 | — | — | US | disclosed |
| EP-1100797-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-6509464-B1 | 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation | PFIZER INC | 2003-01-21 | — | — | US | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| EP-1098894-B1 | FKBP INHIBITORS | PFIZER LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | GLIAMED, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6372736-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-04-16 | — | — | US | disclosed |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | GUILFORD PHARMACEUTICALS INC. | 2002-04-11 | — | — | US | disclosed |
| EP-1100797-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | Pfizer Limited (GB) | 2001-05-23 | — | — | EP | disclosed |
| US-6166011-A | FKBP inhibitors | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000005232-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052410-A1 | Administering to the animal suffering from neurological disorders an amide compound having an affinity for FKBP-type immunophilins | FKBP14, FKBP1A, FKBP2 | TACR1 496/4885FKBP4 5/4885XIAP 1078/4885 |
| US-20020042377-A1 | Rotamase enzyme activity inhibitors | BDNF, FKBP1A, FKBP14 | TACR1 2316/4885FKBP4 6/4885XIAP 488/4885 |
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | FKBP1A, FKBP4, FKBP1B | TACR1 2412/4885FKBP4 2/4885XIAP 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.